The Safety and Efficacy of Zolpidem in Insomniac Patients: A Long-Term Open Study in General Practice
The DOI matches its Crossref record.
Abstract
The safety and efficacy of 10 or 20 mg/day zolpidem, a new hypnotic belonging to the imidazopyridine class, were studied over a 180-day period in 96 patients with sleep disorders. The treatment was continued for a further 180 days by 49 of these patients. Follow-up information from 21 patients who discontinued treatment after 180 days showed no rebound insomnia or withdrawal signs. Efficacy of treatment with respect to reduction of sleep onset latency and number of nocturnal wakenings, and improvement in duration of sleep, quality of sleep and morning wakenings was found in nearly 90% of patients and was maintained in those patients who continued treatment for 360 days. This efficacy was achieved with a stable percentage of patients receiving 10 mg/day and 20 mg/day zolpidem from day 30 to the final visit. Zolpidem, therefore, has been shown to be an effective and safe hypnotic, and to be devoid of rebound and withdrawal effects. La sécurité d'utilisation et l'efficacité du 10 ou 20 mg par jour de zolpidem, un nouvel hypnotique appartenant à la classe des imidazopyridines, ont été étudiées sur une période de 180 jours chez 96 patients souffrant de troubles du sommeil. Le traitement s'est poursuivi pendant 180 jours supplémentaires chez 49 de ces patients. Le suivi de 21 patients ayant cessé le traitement au bout de 180 jours n'a montré ni rebond d'insomnie, ni syndrome de sevrage. L'efficacité du traitement se mesure par la reduction du temp d'endormissement et le nombre de réveils noctures, ainsi que l'amélioration de la durée du sommeil, de la qualité du sommeil et du réveil au matin ont été retrouvés chez près de 90% des patients; ces effets se sont maintenus chez les patients qui ont poursuivi le traitement pendant 360 jours. Cette efficacité a été obtenue pour un pourcentage assez constant de patients qui ont reçu 10 mg par jour de zolpidem, puis 20 mg par jour du 30 ème jour à la fin du traitement. Pour ces raisons, le zolpidem, s'est donc révélé être un hypnotique efficace et sûr, dépourvu d'effets de rebond et de sevrage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zolpidem: A Review of Its Use in the Management of Insomnia
Swainston Harrison, T., & Keating, G. M. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00008 · Cited by 323
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317
Behavioral Pharmacology of Zolpidem Relative to Benzodiazepines A Review
Rush, C. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00102-6 · Cited by 260
Mendelson, W. (2004) · Sleep Medicine Reviews · doi:10.1016/s1087-0792(03)00042-x · Cited by 142
Comparative Tolerability of Newer Agents for Insomnia
Zammit, G. (2009) · Drug Safety · doi:10.2165/11312920-000000000-00000 · Cited by 98
Metadata
- Authors
- Maarek, L., Cramer, P., Attali, P., Coquelin, J. P., & Morselli, P. L.
- Venue
- Journal of International Medical Research
- Publisher
- SAGE Publications
- Published
- 1992-04
- Volume
- 20
- Issue
- 2
- Pages
- 162-170
- ISSN
- 0300-0605 (ISSN-L)
- 1473-2300
- OpenAlex
- W1956069773
- Cited by
- 66
- References
- 0
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Safety and Efficacy of Zolpidem in Insomniac Patients: A Long-Term Open Study in General Practice. https://app.cochat.ai/papers/10.1177/030006059202000208
- The paper
- Maarek, L., Cramer, P., Attali, P., Coquelin, J. P., & Morselli, P. L. (1992). The Safety and Efficacy of Zolpidem in Insomniac Patients: A Long-Term Open Study in General Practice. Journal of International Medical Research. https://doi.org/10.1177/030006059202000208
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.